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Overexpression of HCN provides advantages for the survival and proliferation
of cancer cells. The addition of Ivabradine blocks HCN channels and affects
intracellular homeostasis of Ca2+. Subsequently, this induces ER-stress and trig-
gers apoptosis. Also, it makes the cancer cells become more sensitive to other
chemotherapeutic agents.
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Abstract
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are
members of the voltage-gated cation channel family known to be expressed
in the heart and central nervous system. Ivabradine, a small molecule HCN
channel-blocker, is FDA-approved for clinical use as a heart rate-reducing
agent. We found that HCN2 and HCN3 are overexpressed in breast cancer cells
compared with normal breast epithelia, and the high expression of HCN2 and
HCN3 is associated with poorer survival in breast cancer patients. Inhibition of
HCN by Ivabradine or by RNAi, aborted breast cancer cell proliferation in vitro
and suppressed tumour growth in patient-derived tumour xenograft models
established from triple-negative breast cancer (TNBC) tissues, with no evident
side-effects on the mice. Transcriptome-wide analysis showed enrichment for
cholesterol metabolism and biosynthesis as well as lipid metabolism pathways
associated with ER-stress following Ivabradine treatment. Mechanistic studies
confirmed that HCN inhibition leads to ER-stress, in part due to disturbed Ca2+
Abbreviations: 4-PBA, 4-Phenylbutyric acid; CI, Combination Index; EC50, half-maximal effective concentration; ER, endoplasmic reticulum; FDA,
U.S. Food and Drug Administration; GO, gene ontology; HCN, hyperpolarization-activated cyclic nucleotide–gated channels; IP3, inositol 1 4
5-trisphosphate; PDTX, patient-derived tumour xenograft; TNBC, triple-negative breast cancer
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
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homeostasis, which subsequently triggered the apoptosis cascade. More impor-
tantly,we investigated the synergistic effect of Ivabradine andpaclitaxel onTNBC
and confirmed that both drugs acted synergistically in vitro through ER-stress
to amplify signals for caspase activation. Combination therapy could suppress
tumour growth of xenografts at much lower doses for both drugs. In summary,
our study identified a new molecular target with potential for being developed
into targeted therapy, providing scientific grounds for initiating clinical trials for
a new treatment regimen of combining HCN inhibition with chemotherapy.
KEYWORDS
ER-stress, HCN, Ivabradine, targeted therapy, triple-negative breast cancer
1 INTRODUCTION
Hyperpolarization-activated cyclic nucleotide-gated chan-
nels (HCN channels; HCN1-4) are members of the voltage-
gated cation channel family. They are mainly located on
the cellular membrane, with the exception that HCN3
tends to accumulate in intracellular compartments.1 HCN
channels are highly selective cation channels1 and are one
of the few that can be activated by hyperpolarization.2
Attention had been focused on HCNs mainly expressed in
the heart and nervous system.1,3 HCN4 is predominantly
expressed in the cardiac conduction system and controls
heart rate.4 Ivabradine is a U.S. Food and Drug Adminis-
tration (FDA)-approved therapeutic HCN channel-blocker
used clinically as a heart rate-reducing agent.5 The drug
selectively blocks the HCN channels,6,7 reducing the spon-
taneous diastolic depolarization in the sinoatrial node,
thereby regulating heart rate.8 HCN activation in hyperpo-
larized cells allows entry of cations, such as Na+ and Ca2+,
into the cells and the efflux of K+ leading to depolariza-
tion of the membrane potential.9,10 A recent report found
HCN2 expressed in non-small cell lung carcinoma cell
lines which are hyperpolarized on exposure to proapop-
totic triggers.11 From the Human Protein Atlas (https://
www.proteinatlas.org/), it was noted thatHCN2 andHCN3
were found to be unfavourable prognostic markers of renal
cancer, and strong cytoplasmic and membranous expres-
sion of HCN3 protein expression was observed in colorec-
tal cancers and several other cases including breast cancer.
In the current study, we found HCN2 and HCN3
are overexpressed in breast cancer cells. We hypothe-
sized that interference of HCN function may affect can-
cer cell viability. We elucidated the underlying molecu-
lar mechanisms and successfully illustrated the efficacy
of inhibiting HCNs to suppress breast cancer in vitro and
in vivo.
2 MATERIALS ANDMETHODS
2.1 Cell culture and transfection
Human breast cell lines MCF-10A, MCF-7, MDA-MB-231,
MDA-MB-453, BT-474 and ZR-75 were purchased from
American Type Culture Collection. All cell lines were
authenticated as mentioned previously.12 All cell lines
were free from mycoplasma, confirmed by PCR. Cell lines
were not passaged more than 50 times. Lipofectamine
2000 (Invitrogen) was employed for the transfection of
plasmids. Oligofectamine (Invitrogen) was used for siRNA
transfection.
2.2 Chemicals
A total of 100 mM of Ivabradine (Sigma), 100 mg/mL
of puromycin (Sigma), 50 mM of sodium phenylbutyrate
(4-PBA; Santa Cruz Biotechnology) and 50 mg/mL of
doxycycline hyclate (Santa Cruz Biotechnology) were dis-
solved in double-distilled water. A total of 50 µM of Pacli-
taxel (Selleckchem) was dissolved in DMSO. Water and/or
saline were used as solvent control in in vitro and in vivo
experiments. Also, 10 mM of Inositol 1,4,5-Trisphosphate
(407137; Sigma) in water was used. A sum of 1 mM of
Fura-2-AM (Invitrogen) stock solution in DMSO was pre-
pared and 10 mg/mL of Hoechst33342 was purchased from
ThermoFisher.
2.3 RNA sequencing
The sequencingwas performed by Centre for Genomic Sci-
ences (The University of Hong Kong). Illumina NovaSeq
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6000 was used for Pair-End 151bp sequencing. Using soft-
ware from Illumina (bcl2fastq), sequencing reads were
assigned. An average of 95% of the bases achieved an accu-
racy of 99.9%.
2.4 Orthotopic xenograft
Female nude mice aged between 5 and 6 weeks were used.
A total of 1 × 107 of MDA-MB-231 or MDA-MB-453 cells
were inoculated onto the mammary fat pad of the mice.
Also, 15 mg/Kg of Ivabradine or water was injected subcu-
taneously daily. For the combined treatment of Ivabradine
and Paclitaxel experiment, both drugswere injected subcu-
taneously, twice a week. All the procedures were reviewed
and approved by HKU Committee on the Use of Live Ani-
mals in Teaching and Research (CULATRNo. 4204–16) for
xenograft model.
2.5 Patient-derived tumour xenografts
(PDTX)
Triple-negative breast cancer (TNBC) patients were
recruited from Pamela Youde Nethersole Eastern Hospital
and Kwong Wah Hospital with approval by Hong Kong
East Cluster Research Ethics Committee (REC Reference
No. HKEC-2016-063) and Kowloon West Cluster Research
Ethics Committee (RECReference No. KW/EX-16-158[103-
11]). All the procedures were reviewed and approved by
HKU Committee on the Use of Live Animals in Teaching
and Research (CULATR No. 4218-16) for patient-derived
tumour xenograft (PDTX) model, and the Institutional
Review Board of the University of Hong Kong/Hospital
Authority Hong Kong West Cluster (HKU/HA HKW IRB
No. UW 16–391) for collection of human tissue. A total of
1 × 107 of the human TNBC cells were inoculated onto the
mammary fat pad of the mice and 15 mg/kg of Ivabradine
or water was injected subcutaneously twice a week for
4 weeks.
2.6 Fluorescent microscopy and
live-cell imaging
Carl Zeiss LSM 700/710 confocal laser scanning micro-
scope system with Diode laser (405 nm), Argon laser
(458/488/514 nm), SPSS laser (561 nm) and HeNe laser (633
nm). The filter cube contained filters for DAPI, DsRed,
EGFP and Cy5. Cells were seeded on a coverslip and
treated with 50 µM of Ivabradine for 72 h. On the day of
imaging, 4 µM of Fura-2-AM was used to treat the cells
for 30 min. The cells were then washed with 1× PBS three
times. The coverslip was mounted on a coverslip cham-
ber. The cells were excited by laser with 405 nm and sig-
nals were collected from EGFP filter at room temperature.
Microplate reader Infinite F200 (Tecan) was employed to
record the fluorescent signal. A total of 10 000 cells were
seeded on 96-well plate and treated with 50 µM of Ivabra-
dine for 72 h. A sum of 4 µM of Fura-2-AM was used to
treat the cells for 30 min. The cells were then washed with
1× PBS three times. The cells were excited by UV Xenon
flashlamp. The signal was recorded with a 570 nm filter at
room temperature. Nikon H600L fluorescent microscope
was used for fluorescence analysis.
2.7 Subcellular fractionation
Subcellular fractionation was performed by using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientific), Subcellular Protein Fractionation Kit (Thermo
Scientific) and Mitochondria Isolation Kit (Thermo Scien-
tific).
2.8 Cell viability
MTT assay was performed (USB, Affymetrix). Clonogenic
assay was performed. Also, 0.01% of crystal violate was
employed to stain the cell colonies.
2.9 Flow cytometry
TUNEL assay was performed using APO-BrdU TUNEL
Assay Kit (Invitrogen). Annexin V/PI staining (Dead Cell
Apoptosis Kit with Annexin V FITC and PI; Invitro-
gen) was performed. BD LSR Fortessa analyser (BD Bio-
sciences) was used for analysing the cells. The cells were
gated by (1) SSC-A versus FSC-A, (2) FSC-W versus FSC-H
and (3) SSC-W versus SSC-H for singlets. The results were
analysed and processed by the software FlowJo V10.
2.10 Luciferase reporters and caspase
3/7 activity assays
The luciferase reporter assay was performed using Dual-
Luciferase Reporter assay system (Promega). Cignal ERSE
Reporter Kit (ATF4 response element; CCS-2032L; Qia-
gen) was purchased for determining ER-stress. Caspase-
Glo 3/7 Assay Systems (Promega) and Cell Event Caspase
3/7 Green Detection Reagent (Invitrogen) were employed
to determine the activity of caspases. The chemilumines-
cence and fluorescent signals generated were recorded by
Infinite F200 (Tecan).
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2.11 Tissue microarray
A cohort totalling 316 breast cancer patients diagnosed
between 1993 and 2003 with pathological and clinical
follow-up data of over 20 years were used for this study. All
cases were retrieved from the records of the Department
of Pathology, Queen Mary Hospital of Hong Kong, with
approval by the Institutional Review Board of The Uni-
versity of Hong Kong (UW 08–147). Clinical pathological
characteristics of the cases are summarized in Supporting
information Table S1.
2.12 Immunohistochemistry
Antibodies used were anti-Ki-67 (M7240; 1:150 Dako), anti-
HCN2 (APC-030; 1:300; Alomone Labs) and anti-HCN3
(APC-057; 1:500; Alomone Labs). Aperio ScanScope sys-
tem (Aperio technology) was used for assessing the protein
expression of HCN2 and HCN3.
2.13 Statistical and pathway
enrichment analysis
METABRIC dataset from TCGA was used. The effect of
Ivabradine on different molecular functions was deter-
mined using databases from Gene ontology (GO),13
Reactome,14 and gene set enrichment analysis (GSEA).15
All numerical data were processed in Excel (Microsoft),
Prism5 (GraphPad), or SPSS25 (IBM). All data were
expressed as mean ± SD from at least three independent
experiments. G*Power software was used to determine the
number of samples required to achieve 80% power.16 We
assumed there was 50% difference between normal and
tumour tissues and the ratio of normal to tumour sam-
ples was 1:7. A sum of 30 normal samples and 210 tumour
samples will be the minimal number of samples from each
group to achieve effective analysis. Mann–Whitney U test
was used to determine the statistical difference between
the expression of HCN2 and HCN3 in normal and tumour
tissues because the data did not pass Shapiro–Wilk normal-
ity test which was a test to determine if the distribution of
data was normally distributed. A two-tailed Students’ t-test
was performed to compare the means of the two sample
groups. Comparison between multiple groups was deter-
mined by one-way analysis of variance (ANOVA) and two-
way ANOVA. Bonferroni test was used as a post-test after
one-way ANOVA to compare means between two groups.
Correlation with survival study of Tissue Microarray data
was analysed by Kaplan–Meier estimates followed by Log-
rank test carried out by SPSS. Cox proportional hazards
regression was used to estimate the association between
clinical-pathological parameters, or HCN scores with sur-
vival. Relative risk (RR) and 95% confidence interval (CI)
were reported. The proportional-hazards assumption was
tested using the Omnibus test, and no major model vio-
lation was observed. Combination Index (CI) of drug-drug
interactionwas calculated by using the formula: CI= [a/A]
+ [b/B] where a is the half-maximal effective concentra-
tion (EC50) of drug 1 in the presence of drug 2; A is the
EC50 of drug 1 without drug 2; b is the EC50 of drug 2 in the
presence of drug 1; B is the EC50 of drug 2 without drug 1.
EC50 is half-maximal effective concentration. CI less than 1
suggested the presence of the synergistic effect.17 EC50 was
calculated using Prism5 (GraphPad) by non-linear regres-
sion (log10[drug] vs. normalized response). P-value of less
than .05 was considered statistically significant.
Detailed procedures, sequences and antibodies are listed
in Supporting information.
3 RESULTS
3.1 HCN2 and HCN3 are overexpressed
in breast cancer cells and associated with
poor prognosis
Using the METABRIC database from TCGA, we found a
significant difference in expression between breast tumour
tissues compared with normal breast tissue in HCN2
(P< .001) andHCN3 (P< .001) but not inHCN1 andHCN4
(Supporting information Figure S1A-D). We also exam-
ined the mRNA levels of HCN1-4 in various breast cancer
cell lines, including the estrogen-receptor positive (MCF-
7, ZR-75), HER2-positive (BT-474) and TNBC (MDA-MB-
231, MDA-MB-453) cells compared with non-neoplastic
MCF-10A breast epithelial cells. We confirmed that only
HCN2 and HCN3 (Supporting information Figure S2A-D)
were upregulated in breast cancer cells. Overexpression of
HCN2 andHCN3 proteins was consistently found in breast
cancer cells (Figure 1A), with BT474 and TNBC cellsMDA-
MB-231,MDA-MB-453 showing themost significant upreg-
ulation. We found both HCN2 and HCN3 were predomi-
nantly localized to the cell membrane (Figure 1B), suggest-
ing that HCN2 and HCN3 could be functionally important
in breast cancer cells.
Using immunohistochemistry to examine HCN2 and
HCN3 protein expression of primary breast cancer in tis-
sue microarray, we confirmed that HCN2 (Figure 1C)
and HCN3 (Figure 1D) were significantly upregulated in
tumour compared with normal breast epithelia. From the
analysis of 316 breast cancer cases, those cases which
showed both high HCN2 and HCN3 expression were
most frequently of the TNBC subtype (68.4%) (Table S2),
prompting us to focus our study on TNBC. Patients with
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F IGURE 1 HCN 2 and HCN3 were overexpressed in breast cancer and associated with poor survival outcomes. A, Protein expressions of
HCN2 and HCN3 were determined in breast cancer cell lines compared with non-neoplastic breast epithelial cell line MCF-10A by western
blot. Actin was used as the loading control. Results were repeated three times and representative images are shown. B, HCN2 and HCN3 were
predominantly localized to the cell membrane. MDA-MB-231 and MDA-MB-453 cells were used, and fractionation was performed to isolate
different cellular fractions. Western blot was employed to determine the expression of the proteins. Lamin B1, PMCA and tubulin were used as
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high HCN2 or HCN3 expression showed poorer overall,
disease-specific survival (Figure 1E and F) and patients
expressing both high HCN2 and HCN3 showed the poor-
est survival when compared with both low expressers
(Figure 1G). Cox-regression analysis (Table 1A) showed
cases with both high HCN2 and HCN3 was statisti-
cally significantly associated with poorer overall survival
(P= .000104; Table 1A) and disease-free survival (P= .013;
Table 1B), which remained significant after multivariate
cox-regression analyses (P = .003; Table 1 and P = .017;
Table 1B) for overall survival and disease-free survival,
respectively. These findings suggest that HCN2 and HCN3
may be oncogenic in breast cancer.
3.2 HCN suppression inhibits TNBC
growth in vitro and in vivo
Knockdown of HCN2 and HCN3 using two independent
shRNAs significantly suppressed proliferation of TNBC
cell lines as revealed by MTT assay (Figure 2A-D and Sup-
porting information Figure S3A and B) and clonogenic
assay (Figure 2E and F). We confirmed that the shRNAs
only hit the designated target but not the other members
of the HCN family (Supporting information Figure S3A
and B). Additionally, we employed Ivabradine, which is
an FDA-approved HCN channel blocker used clinically
to treat chronic angina,5 to target HCN. The effect on
cancer cell viability was dose-dependent, with more than
50% reduction in both cell lines at Ivabradine concen-
trations greater than 5 µM (Supporting information Fig-
ure S4A and B). Results from clonogenic assay suggested
that 5 µM Ivabradine could effectively suppress cell pro-
liferation of MDA-MB-231 and MDA-MB-453 but not the
non-neoplastic cells MCF-10A (Figure 2G). Furthermore,
Ivabradine treatment could induce apoptosis in breast
cancer cells but not MCF-10A as revealed by Annexin
V/PI staining (Figure 2H and Supporting information Fig-
ure S4C), consistent with increased levels of active caspase
3, 7 and 9 (Figure 2I). Ivabradine treatment, however, did
not affect the expression ofHCN2 andHCN3 in TNBC cells
(Supporting information Figure S4D).
We validated the tumour-suppressive effect of Ivabra-
dine in xenograft models. The nude mice were treated
with either Ivabradine or water subcutaneously (15 mg/kg
daily). The results showed a significant reduction in
tumour volume for both MDA-MB-231 (Figure 3A) and
MDA-MB-453 (Figure 3B) xenografts. Consistently, Ivabra-
dine could significantly reduce the percentage of Ki-67 pos-
itive cells (Figure 3C) and enhance the level of cleaved cas-
pases 3, 7 and 9 in tumour samples shown by western blot
(Figure 3D). Also, we confirmed that Ivabradine treatment
did not affect the expression of HCN2 and HCN3 in vivo
(Supporting information Figure S5). Similarly, depletion of
HCN2 or HCN3 by shRNA could significantly reduce the
growth rate of the tumours in vivo (Supporting informa-
tion Figure S6A and B).
We tested the effect of Ivabradine on ten PDTX models
generated from TNBC cases. The mice were treated with
either Ivabradine (15 mg/Kg twice weekly) or water. The
results showed that Ivabradine could significantly reduce
tumour volume (Figure 3E) and tumourweight (Figure 3F)
in 8 out of 10 PDTX models (Supporting information Fig-
ure S7).Western blot showed the two cases, which are non-
responsive to Ivabradine (PDTX18 and PDTX19) and had
low HCN2 and HCN3 expression (Figure 3G). Ivabradine
also exerted a dose-dependent effect in the PDTX model,
the minimal effective dosage being 5 mg/kg twice weekly
(Figure 3H) but had no effect on HCN2 and HCN3 expres-
sion (Supporting information Figure S8).
Ivabradine could reduce the heart rate 20 min imme-
diately after the injection, consistent with the known
effect of the drug (Supporting information Figure S9A).
However, its cumulative effect of 4 weeks treatment
nuclear (N), cell membranous (M) and cytoplasmic (C) markers, respectively. Results were repeated three times and representative images are
shown. C, HCN2 was overexpressed in breast cancer. IHC was employed to determine the expression of HCN2 in normal (N = 38) and tumor
tissues (N = 279). Mann−Whitney U test (P = 7.75 × 10−14) and chi-square test (P = 7.57 × 10−11) were employed to determine the statistical
significance. The scale bar represents 18 µm. D, HCN3 was overexpressed in breast cancer. IHC was employed to determine the expression of
HCN3 in normal (N = 58) and tumor tissues (N = 300). Mann−Whitney U test (P = 2.31 × 10−18) and chi-square test (P = 9.49 × 10−10) were
employed to determine the statistical significance. The scale bar represents 18 µm. E, Breast cancer patients with high expression of HCN2
were associated with poorer survival outcomes. The patients with high expression of HCN2 (N = 142) in their breast cancer showed poorer
overall survival (P = .0005, log-rank test) and poorer disease-specific survival (P = .020, log-rank test). Red line represents the patient group
with high HCN2 expression while blue line represents the patient group with low HCN2 expression. F, Breast cancer patients with high
expression of HCN3 were associated with poorer survival outcomes. The patients with high expression of HCN3 (N = 142) in their breast
cancer showed poorer overall survival (P = .000088, log-rank test) and poorer disease-specific survival (P = .009, log-rank test). Red line
represents the patient group with high HCN3 expression while blue line represents the patient group with low HCN3 expression. G, The
patients with high expression of both HCN2 and HCN3 (N = 100) would have the poorest survival outcome when compared with low
expressers of both (N = 91), for both overall survival (P = 5.7 × 10−5, log-rank test) and disease-specific survival (P = .011, log-rank test). Red
line represents the patient group with both high HCN2 and HCN3 expression while blue line represents the patient group with both low
HCN2 and HCN3 expression. High expression of HCN2 and HCN3 was defined that the staining score is more than the median score.
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TABLE 1A Cox regression analyses of overall survival
Univariate analysis
Clinical-pathological parameters RR (95% CI) P value
Age (n = 306) 1.785 (1.256, 2.535) .001
T-stage (n = 199) 2.079 (1.095, 3.947) .025
Lymph-node involvement (n = 274) 1.421 (0.979, 2.063) .064
Tumor-grade (n = 274) 1.099 (0.757, 1.595) .62
Histological type (n = 296) 0.885 (0.553, 1.415) .610
Estrogen receptor status (n = 225) 0.74 (0.463, 1.182) .207
HER2 status (n = 186) 1.228 (0.669, 2.255) .507
Triple-negative (n = 202) 1.219 (0.626, 2.375) .56
Tumor size (n = 115) 1.7 (0.882, 3,277) .113
Cases with Hi-HCN2 cytoplasm score (n = 269) 1.952 (1.331, 2.861) .001
Cases with Hi-HCN3 cytoplasm score (n = 291) 2.029 (1.413, 2.913) .000125
Both Hi-HCN2 & Hi-HCN3 cytoplasm score (n = 189) 2.567 (1.594, 4.132) .000104
Multivariate analysis
Clinical-pathological parameters RR (95% CI) P value
Age (n = 190) 1.869 (1.171, 2.984) .009
T-stage (n = 190) 1.565 (0.811, 3.021) .182
Cases with Hi-HCN2 cytoplasm score (n = 190) 2.01 (1.231, 3.284) .005
Multivariate analysis
Clinical-pathological parameters RR (95% CI) P value
Age (n = 189) 1.786 (1.115, 2.859) .016
T-stage (n = 189) 2.279 (1.198, 4.334) .012
Cases with Hi-HCN3 cytoplasm score (n = 189) 1.983 (1.232, 3.19) .005
Multivariate analysis
Clinical-pathological parameters RR (95% CI) P value
Age (n = 133) 1.809 (1.015, 3.225) .044
T-stage (n = 133) 2.75 (1.25, 6.051) .012
Both Hi-HCN2 & Hi-HCN3 cytoplasm score (n = 133) 2.611 (1.394, 4.888) .003
did not induce abnormal heart rhythm in the mice
after 4 weeks of treatment (Supporting information Fig-
ure S9B). Cage-side observation of mice treated with
Ivabradine showed no observable adverse effect (>10%
weight loss in body weight, signs of illness, or abnor-
mal behaviour). Also, there was no sign of liver toxi-
city as the serum aspartate transaminase and alanine
transaminase levels remained the same as the control
group (Supporting information Figure S9C). These find-
ings suggest that Ivabradine was relatively free of obvious
side-effects.
3.3 Transcriptome-wide analysis
showed HCN inhibition activates ER-stress
response leading to apoptosis
We performed RNA sequencing to reveal the effect of
Ivabradine on global cellular activities in non-cancerous
epithelial breast cells MCF-10A and TNBC cells MDA-
MB-231 and MDA-MB-453. The findings showed Ivabra-
dine treatment resulted in a distinct expression profile in
MCF-10A cells compared with that in TNBC cells (Fig-
ure 4A; Supporting information Table S3). We found 177
genes commonly and specifically upregulated by Ivabra-
dine in TNBC cells (Figure 4B). GO enrichment analy-
sis identified the biological processes that were signifi-
cantly affected by Ivabradine in TNBC, the top 30 bio-
logical processes as shown (Figure 4C). Further analy-
sis using data retrieved from Reactome,14 identified the
pathways that were significantly affected by Ivabradine in
TNBC (Figure 4D). The results from GO and Reactome
analysis suggested that Ivabradine could alter lipid and
cholesterol metabolism. As activation of ER-stress path-
ways is known to alter lipid and steroid metabolism,18
these findings suggest that Ivabradine may induce ER-
stress. In addition, we employed GSEA to determine the
effect of Ivabradine on different molecular mechanisms.
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TABLE 1B Cox regression analyses of disease-specific survival
Univariate analysis
Clinical-pathological parameters RR (95% CI) P value
Age (n = 306) 0.837 (0.541, 1.296) .426
T-stage (n = 199) 1.649 (0.729, 3.731) .23
Lymph-node involvement (n = 274) 1.967 (1.208, 3.201) .007
Tumor-grade (n = 274) 1.807 (1.123, 2.907) .015
Histological type (n = 296) 0.89 (0.49, 1.615) .701
Estrogen receptor status (n = 225) 0.57 (0.338, 0.962) .035
HER2 status (n = 186) 1.333 (0.66, 2.691) .423
Triple-negative (n = 202) 1.651 (0.803, 3.392) .173
Tumor size (n = 115) 2.419 (0.969, 6.036) .058
Cases with Hi-HCN2 cytoplasm score (n = 269) 1.731 (1.082, 2.769) .022
Cases with Hi-HCN3 cytoplasm score (n = 291) 1.822 (1.156, 2.871) .01
Both Hi-HCN2 & Hi-HCN3 cytoplasm score (n = 189) 2.154 (1.178, 3.937) .013
Multivariate analysis
Clinical-pathological parameters RR (95% CI) P value
Lymph-node involvement (n = 177) 1.473 (0.82, 2.647) .195
Tumor-grade (n = 177) 1.581 (0.819, 3.05) .172
Estrogen receptor status (n = 177) 0.71 (0.373, 1.352) .297
Cases with Hi-HCN2 cytoplasm score (n = 177) 1.911 (1.031, 3.544) .04
Multivariate analysis
Clinical-pathological parameters RR (95% CI) P value
Lymph-node involvement (n = 186) 1.42 (0.801, 2.518) .23
Tumor-Grade (n = 186) 1.687 (0.88, 3.235) .115
Estrogen receptor status (n = 186) 0.715 (0.38, 1.343) .297
Cases with Hi-HCN3 cytoplasm score (n = 186) 2.337 (1.296, 4.215) .005
Multivariate analysis
Clinical-pathological parameters RR (95% CI) P value
Lymph-node involvement (n = 125) 1.748 (0.853, 3.586) .127
Tumor-grade (n = 125) 2.563 (1.003, 6.548) .049
Estrogen receptor status (n = 125) 0.747 (0.353, 1.582) .447
Both Hi-HCN2 & Hi-HCN3 cytoplasm score (n = 125) 2.724 (1.197, 6.196) .017
Top 10 of the most significantly affected mechanisms
in downregulation (Figure 4E; Supporting information
Tables S4 and S5) and upregulation (Figure 4F; Sup-
porting information Tables S6 and S7) are shown. From
the analysis, Ca2+ signalling pathway showed signifi-
cant downregulation (Figure 4E) while ATF6-mediated
unfolded protein response and apoptotic signalling path-
way in response to ER-stress were found to be enriched
(Figure 4F). HCN channels are responsible for the entry
of cations into cells3,19 including the import of Ca2+.9,10,19
Since Ivabradine targets HCN channels in affecting ion
homeostasis, including that of Ca2+, it could induce
ER-stress.
3.4 Targeting HCN channels causes
ER-stress and triggers apoptosis in breast
cancer
To examine whether induction of ER-stress was through
perturbation of Ca2+ homeostasis, we employed live-cell
imaging to examine Ca2+ levels in Ivabradine-treated cells.
We found that Ivabradine could reduce cytoplasmic Ca2+
levels in breast cancer cell lines but not in MCF-10A cells
that do not overexpress HCN (Figure 5A). As a positive
control, when MCF-10A was further treated with Inosi-
tol 1 4 5-trisphosphate (IP3), a chemical that binds to IP3
receptors on the ERmembrane to trigger Ca2+ release, this
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F IGURE 2 Suppression of HCN2 and HCN3 inhibited breast cancer cell growth in vitro. The knockdown of HCN2 could suppress the
cell proliferation of TNBC cells A, MDA-MB-231 and B, MDA-MB-453 in the short term as assessed by MTT assay. Two independent shRNAs
against HCN2, shHCN2.1 and shHCN2.2 were used. Results were shown as mean ± SD from three independent experiments. The knockdown
of HCN3 could suppress the cell proliferation of TNBC cells C, MDA-MB-231 and D, MDA-MB-453 in the short term as assessed by MTT assay.
Two independent shRNAs against HCN3, shHCN3.1 and shHCN3.2 were used. Results were shown as mean ± SD from three independent
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resulted in increased cytoplasmic Ca2+ level (Supporting
information Figure S10), confirming that Ivabradine was
ineffective to alter cytoplasmic Ca2+ levels in MCF-10A.
Interference in Ca2+ homeostasis can induce ER-
stress (unfolded protein response),20 which will eventu-
ally induce apoptosis.21 We employed luciferase reporter
containing a response element of ATF4, a transcriptional
factor activated under ER-stress to determine the effect of
Ivabradine on ER-stress.22 The results showed that 10 µM
Ivabradine significantly promoted the luciferase activity in
breast cancer cells but not in MCF-10A (Figure 5B). Con-
sistently, the levels of GRP78 and CHOP, which are two
protein markers of ER-stress, were significantly increased
after Ivabradine treatment inMDA-MB-231 andMDA-MB-
453 but not in MCF-10A cells (Figure 5C). Furthermore,
CHOP was enriched in the nucleus after Ivabradine treat-
ment (Figure 5D), suggesting that ER-stress induced by
Ivabradine could not be resolved and cells were commit-
ted to apoptosis. These effects were validated in xenograft
tumours (Supporting information Figure S11).
To further establish whether ER-stress is the central
mediator for Ivabradine-induced apoptosis,4-PBA com-
monly used to alleviate ER-stress was employed.23 We con-
firmed that 4-PBA could reduce the degree of ER-stress
induced by Ivabradine (Figure 5E) and that 4-PBA could
abolish the suppressive effect of Ivabradine on cell viabil-
ity of breast cancer cells but not of MCF-10A (Figure 5F).
Subsequently, we showed that while 10 µM Ivabradine sig-
nificantly increased the activities of the caspases, the addi-
tion of 4-PBA compromised the effect of Ivabradine on cas-
pase activities (Figure 5G). Flow cytometry confirmed that
4-PBA could significantly reduce the proportion of apop-
totic cells in Ivabradine-treated breast cancer cells but not
in MCF-10A (Figure 5H). These results support our con-
clusion that Ivabradine induces cell death via ER-stress.
Since breast cancer cells showed increased expression
of both HCN2 and HCN3, we investigated the signifi-
cance of each to ER-stress. Knockdown of either HCN2 or
HCN3 by siRNA (Supporting information Figure S12A-D)
could induce ER-stress as revealed by the luciferase assay
(Figure 6A and B). Moreover, an enhanced level of free
cytochrome c in the cytoplasm was demonstrated by west-
ern blot in either HCN2 or HCN3 knockdown cells (Fig-
ure 6C). Caspase activities were significantly enhanced in
the breast cancer cells but not in MCF-10A (Figure 6D-F),
indicating the apoptosis cascade had been activated, lead-
ing to reduction of viable cells (Supporting information
Figure S12E and F).We also validated significantly upregu-
lated expression of ER-stressmarkersGRP78,ATF4, CHOP
and apoptosis marker BIP, BIM, cleaved caspase 3 in the
tumour xenografts with HCN2 or HCN3 knockdown (Fig-
ure 6G andH). These data suggest that Ivabradine induced
apoptosis of breast cancer cells acts through inhibition of
overexpressed HCN2 and HCN3, and not a result of non-
specific cytotoxicity.
To further demonstrate Ivabradine treatment does
indeed depend on HCN2 and HCN3, knockdown exper-
iments were performed (Supporting information Fig-
ure S12A-F). While knockdown of HCN2 and HCN3 indi-
vidually each compromised the effect of Ivabradine (Sup-
porting information Figure S13A and B), double knock-
down of HCN2 and HCN3 could further compromise its
effect on cell viability in both cell lines (Supporting infor-
mation Figure S13C and D). To assess the off-target effects
on other HCN family members, HCN1 and HCN4 were
silenced in turn in cancer cells (Supporting information
Figure S14A and B). Knockdown of HCN1 and HCN4 did
not affect Ivabradine efficacy (Supporting information Fig-
ure S14C and D).
3.5 The synergistic effect of Ivabradine
with paclitaxel on TNBC
We compared the effect of Ivabradine, doxorubicin and
paclitaxel on cell viability and apoptosis in MDA-MB-231,
experiments. Two-way ANOVA revealed there was a statistically significant interaction between the HCN2/3 knockdown and time (A:
F = 2.71, P < .05; B: F = 4.71, P < .001; C: F = 6.00, P < .001; D: F = 7.43, P < .001). Statistical significance between shCtrl and shHCN2.1 or
shHCN2.2 or between shCtrl and shHCN3.1 or shHCN3.2 at each time point was determined by Bonferroni test. *, ** and *** represent
P < .05, P < .01 and P < .001 respectively. The knockdown of either HCN2 or HCN3 could suppress the cell proliferation of TNBC cells E,
MDA-MB-231 and F, MDA-MB-453 in the long term as determined by clonogenic assays. Results were shown as mean ± SD from three
independent experiments. One-way ANOVA was used. Statistical significance between shCtrl and shHCN2.1/shHCN3.1 or
shHCN2.2/shHCN3.2 was determined by Bonferroni test. *** represents P < .001. G, Inhibition of HCNs by Ivabradine could suppress the cell
proliferation of TNBC cells MDA-MB-231 and MDA-MB-453 but not non-neoplastic breast epithelial cells MCF-10A in a clonogenic assay. The
cells were incubated with 5 µM of Ivabradine for 2 weeks. Results were shown as mean ± SD from three independent experiments. Students’
t-test was used. *** represents P < .001. H, Ivabradine significantly induced apoptosis in MDA-MB-231 and MDA-MB-453 but not MCF-10A. A
total of 50 µM of Ivabradine was used to treat cells for 48 h. FITC-Annexin V/PI staining was employed. Cells were analysed by flow cytometry.
Results were shown as mean ± SD from three independent experiments. Students’ t-test was used to determine the statistical significance
between H2O and Ivabradine treated groups. *** represent P < .001. I, Ivabradine treatment led to the activation of caspases 3, 7 and 9, as
determined by western blot. Actin was used as the loading control. Representative images shown from three independent experiments.
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F IGURE 3 Ivabradine suppressed TNBC tumor growth in vivo. A, A comparison of tumours isolated from nude mice treated with 15
mg/kg of Ivabradine (N = 5) or water (N = 5) administered subcutaneously daily for 4 weeks. MDA-MB-231 was used to establish the
xenografts. The graph shows the change in tumor volume with the time between Ivabradine and water-treated groups. Results were shown as
mean ± SD from five tumours. Students’ t-test was used. ** represents P < .01. B, A comparison of tumours isolated from nude mice treated
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MDA-MB-453 and MCF-10A. Ivabradine could suppress
cell proliferation and induce apoptosis of breast cancer
cells as effectively as Paclitaxel and Doxorubicin but is
much less toxic to non-neoplastic MCF-10A cells (Sup-
porting information Figure S15A-F). Although Ivabradine
alone could suppress the proliferation of tumour cells in
vitro (5 µM) and in vivo (5 mg/kg), it could not induce
tumour regression. Therefore, we explored the possibility
of combining paclitaxel with Ivabradine for enhancing the
therapeutic effect in TNBC.
We determined the value of EC50 of paclitaxel (Figure 7A
and B) and Ivabradine (Figure 7C and D) with the use of
ER-stress luciferase reporter assay. In addition, we evalu-
ated the effect of the addition of Ivabradine on ER-stress
mediated by paclitaxel. The results showed that the addi-
tion of Ivabradine made a left shift to the response curve
(Figure 7E and F). EC50 of paclitaxel at different concentra-
tions of Ivabradine was determined (Figure 7G), with val-
ues decreasing with increasing Ivabradine concentrations.
To determine whether or not there was synergistic effect,
the concentrations of combined treatment that result in
50% reduction in ER-stress response were next calculated
to give corresponding CI values. The CI values of Ivabra-
dine and Paclitaxel were less than 1 (CI < 1), supportive
that combining Ivabradine and Paclitaxel has indeed a syn-
ergistic effect on inducing ER-stress.
We determined the dose-dependent effect of paclitaxel
and Ivabradine on caspase activities. The results show that
5 nM of paclitaxel (Figure 7H and I) and 10 nM of Ivabra-
dine (Figure 7J and K) were the highest concentration of
the drugs that would not activate caspases. While 5 nM of
paclitaxel alone could not activate caspase 9 and caspase 3,
5 nM of paclitaxel together with 10 nM of Ivabradine could
significantly induce ER-stress and activate caspases (Fig-
ure 7L). The addition of 4-PBA could abolish the effect of
paclitaxel and Ivabradine on the activities of caspases (Fig-
ure 7M and N), suggesting that the activation of caspases
in the cancer cells treated with paclitaxel and Ivabradine
was mediated by ER-stress.
Consistently in the xenograft model, a low dose of
Ivabradine (1 mg/kg) or paclitaxel (2 mg/kg) alone, given
twice weekly, did not affect tumour volume (Figure 7P)
or did not affect the expression of HCN2 and HCN3 (Sup-
porting information Figure S16). However, synergistically,
they could abort tumour growth (Figure 7O-Q). Our find-
ings, therefore, highlight that cotreatment of Ivabradine
and paclitaxel could be a possible treatment strategy for
TNBC.
4 DISCUSSION
Breast cancer is the most common female cancer
worldwide.24 Up to 10–15% of breast cancers are triple-
negative, lacking targetable proteins for treatment.25
TNBC have aggressive clinical behavior26 with cyto-
toxic chemotherapy being the mainstay of treatment for
these patients. In this study, we present an attractive
novel molecular target in breast cancer, with a focus
on TNBC, and demonstrate that targeting HCN chan-
nels could significantly suppress breast cancer growth.
More importantly, we found a significant synergistic
with 15 mg/Kg of Ivabradine (N = 4) or water (N = 4) administered subcutaneously daily for 4 weeks. MDA-MB-453 was used to establish the
xenografts. The graph showed the change in tumor volume with the time between Ivabradine and water-treated groups. Students’ t-test was
used to compare tumor sizes at the various time points between the Ivabradine and water-treated groups. Results were shown as mean ± SD
from four tumours. * and ** represent P < .05 and P < .01, respectively. C, Treatment with Ivabradine could suppress cell proliferation in
tumours developed from MDA-MB-231 (Panel A) and MDA-MB-453 (Panel B). IHC was employed to determine the expression of cell
proliferation marker Ki-67. Results were shown as mean ± SD from five MDA-MB-231 tumours and four MDA-MB-453 tumours. Students’
t-test was used. * and ** represent P < .05 and P < .01, respectively. The scale bar represents 18 µm. D, Ivabradine could activate caspases 9, 7
and 3. Protein lysates from three individual tumor samples were collected. Western blot was performed to determine the expression of cleaved
caspase 3. Actin was used as the loading control. E, Ivabradine treatment could significantly reduce the volume of tumours in PDTX models.
Ten PDTX models were tested. A total of 15 mg/kg Ivabradine was administered subcutaneously twice a week for 4 weeks. Each spot
represented the average tumor volume of each of the PDTX models. Results were shown as mean ± SD from ten PDTX models. Students’
t-test was used. * and ** represent P < .05 and P < .01, respectively. F, Ivabradine treatment could significantly reduce the weight of tumours
in PDTX models. Ten PDTX models were tested. A total of 15 mg/kg Ivabradine was administered subcutaneously twice a week for 4 weeks.
Each spot represented the average tumor weight of each of the PDTX models. Results were shown as mean ± SD from ten PDTX models.
Mann–Whitney U test was used. ** represents P < .01. G, Expression of HCN2 and HCN3 in tumours from PDTX samples compared with
normal breast lysate (1346-N). Western blot was employed to detect the expression of HCN2 and HCN3. Actin was used as the loading control.
H, The change of tumor volume in response to different dosages of Ivabradine given twice weekly for 4 weeks. PDTX5 was used. Tumor
images were shown in Panel A and the graph showing the change in tumor volume was shown in Panel B. Two-way ANOVA revealed there
was no statistically significant interaction between the effects of the dosage and the treatment length (F = 3.54, P < .001). Bonferroni was used
as a post-test after two-way ANOVA to determine the statistical significance between water control and different dosages of Ivabradine at each
time point. *, ** and *** represent P < .05, P < .01 and P < .001.
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F IGURE 4 RNA-seq analysis revealed transcriptome changes following inhibition of HCN. A, Ivabradine exerted distinctively different
effects on TNBC cells compared with non-cancerous breast cells. MDA-MB-231, MDA-MB-453 and MCF-10A were used. The cells were either
treated with 100 µM of Ivabradine or water for 72 h. RNA sequencing was performed to determine the gene expression profile. Gene
expression levels were determined by transcript per millions (TPM). The differential expressions of genes in each of the cell lines between 72 h
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effect of Ivabradine with paclitaxel in vitro and in vivo,
providing preclinical evidence for the combination
treatment.
We examined the expression levels of the four HCN iso-
forms (HCN1-4) using cell lines from publicly available
TCGA database, and on breast cancer patient biopsies by
IHC and found that only HCN2 and HCN3 are overex-
pressed in breast cancer cells (Figure 1A-D and Supporting
information Figure S1 and S2). We inferred that HCN over-
expression could be oncogenic, hence, tested the effects
of HCN inhibition by shRNA (Figure 2A-F) or by chemi-
cal inhibitor, Ivabradine (Figure 2G-I and 3). We showed
that Ivabradine could reduce cell proliferation and induce
cell apoptosis in cancer cells, (Figure 2G-I, 3A-D and Sup-
porting information Figure S4). This effect of Ivabradine
could be replicated with the use of shHCN cell lines both
in vitro (Figure 2E and F; 6D-H) and in vivo (Supporting
information Figure S6), which excludes the possibility of
non-specific Ivabradine cytotoxicity.
Comparing the efficacy of Ivabradine and paclitaxel in
inhibiting cancer growth in the cell lines, we confirmed
that, while as effective as paclitaxel in the TNBC cell
lines, Ivabradine does not affect MCF-10A, demonstrat-
ing its superiority over conventional chemotherapy (Sup-
porting information Figure S15). Using TNBC PDTX mod-
els to demonstrate the efficacy of Ivabradine, significant
tumour suppression was demonstrated in PDTX models
that expressed highHCN2 andHCN3 (Figure 3E-G). PDTX
models, being constructed from patients’ tumour tissues,
more faithfully resemble the original tumors,27 suggest-
ing a similar response can be expected in breast cancer
patients. HCN4 is the major isoform that controls heart
rate, as it is the dominant isoform in the sinoatrial node
and other parts of the cardiac conducting system.1,28 Based
on our results, only HCN2 and HCN3 are overexpressed in
breast cancer. Therefore, the future effort can be made to
develop a drug that recognizes explicitly HCN2 and HCN3
only, which would be expected to be more cancer-specific
than Ivabradine.
Our transcriptome-wide analysis showed that among
the pathways found to be enriched in Ivabradine-treated
TNBC cells, were the cholesterol metabolism, lipid
metabolism and cholesterol biosynthesis pathways asso-
ciated with ER-stress and two other pathways associated
with apoptosis signature (Figure 4C and D). Luciferase
reporter assay confirmed that ATF4 activity was enhanced
by Ivabradine (Figure 5B). ATF4 is a transcription factor
that regulates lipid metabolism, including sterol biosyn-
thesis, and its activity is enhanced under ER-stress.29 ER-
stress is reported to modulate lipid metabolism by altering
gene expression.18 Through GSEA, we found that Ivabra-
dine could downregulate Ca2+ signalling pathway (Fig-
ure 4E, Supporting information Table S4) and upregulate
ATF6-mediated unfold protein response and apoptotic sig-
nalling pathway in response to ER-stress (Figure 4F, Sup-
porting information Table S6). Thus, enrichment for the
pathways observed in Ivabradine-treated cells reflects the
induction of ER-stress (Figure 5C). Since HCN channels
are ion channels that are permeable to cations, it is possi-
ble that the induction of ER-stress may be due in part to
disturbance of intracellular Ca2+ levels. Ca2+ is responsi-
ble for regulating cellular activities, such as endoplasmic
reticulum (ER)-stress regulation,30 and ER-stress induced
cell death has been reported when Ca2+ homeostasis is
perturbed.31 Our results demonstrated that blockingHCNs
impaired the Ca2+ homeostasis in cancer cells that overex-
press HCN2 and HCN3, resulting in lower levels of intra-
cellular Ca2+ (Figure 5A) in the cells, which could trig-
ger ER-stress response (Figure 5B-D) and subsequently
commit cells to apoptosis. HCN2 has been shown to be
expressed in non-small-cell lung carcinoma, and patch-
clamp experiments showed hyperpolarization of the can-
cer cells on exposure to proapoptotic trigger.11 Moreover, it
demonstrated that HCN2 was necessary for influx of Ca2+
into cells. This supports our hypothesis that HCN channels
when overexpressed in breast cancer cells may be func-
tional and with an oncogenic effect. Further in vivo sup-
port of this oncogenic effect is reflected in our HCN2 and
Ivabradine-treated and water control were determined. The results from MDA-MB-231 and MDA-MB-453 were grouped as TNBC. The mean
value of the differential expression level of each of the genes from MDA-MB-231 and MDA-MB-453 was calculated. A heatmap was plotted to
show the distinctive effect of Ivabradine on differential gene expression profiles between normal breast and TNBC cells. B, Venn diagram was
plotted to show the number of genes commonly and upregulated explicitly in MDA-MB-231 and MDA-MB-453 compared with MCF-10A. A
total of 177 genes were found. C, Gene ontology enrichment analysis was performed to identify the biological processes that were significantly
affected based on these 177 genes. The top 30 biological processes were shown. Black arrows highlight steroid and cholesterol
metabolic/biosynthetic processes. D, Pathway enrichment analysis was performed to identify the cellular pathways that were significantly
affected by Ivabradine treatment. Information from Reactome was retrieved to perform the analysis. All potentially affected pathways were
shown. Black arrows highlight steroid/lipid metabolic and cholesterol biosynthesis pathways. Red arrows highlight apoptosis-related
pathways. E, The top 10 gene sets being downregulated in Ivabradine-treated TNBC cells. F, The top 10 gene sets being upregulated in
Ivabradine-treated TNBC cells. Gene expression profiles of MDA-MB-231 and MDA-MB453 treated with H2O and Ivabradine were compared.
Commonly affected pathways were retained. NES is normalized enrichment score which is the primary statistic for examining gene set
enrichment results.
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F IGURE 5 Inhibition of HCN channels reduced the level of intracellular Ca2+ and triggered ER-stress. A, Ivabradine depleted
intracellular Ca2+ levels in breast cancer cell lines but not in normal epithelial cell line MCF-10A. A total of 4 µM of Fura-2 was used to stain
intracellular calcium ions for 30 min. Live cell imaging was performed to capture the image (Panel A). Infinite F200 microplate reader was
employed to record the fluorescent signal from 10 000 cells (Panel B). Results were shown as mean ± SD from three independent
experiments. Students’ t-test was employed to determine statistical significance between H2O and Ivabradine-treated groups. *** represents
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HCN3 expression in over 200 primary breast cancerswhich
showed a significant correlationwith poorer survival. (Fig-
ure 1E-G; Table 1).
Apoptotic stimulus can alter ionic gradients across the
plasma membrane leading to depolarization of the plasma
membrane potential.32 It is not surprising that cancer
cells have developed strategies such as overexpression of
ion-channels to counteract apoptotic stimulus by induc-
ing hyperpolarization.33 Ion-channels are located on the
plasma membrane, some overexpressed in cancer cells,
and were once considered ideal drug targets since drugs,
exerting their effect in the extracellular space.34 Target-
ing various ion-channels overexpressed in different can-
cer types have been reported to exert antitumor effect.35
Inhibition of voltage-gated sodium (Na+) channels have
been shown to suppress tumour metastasis,36 while inhi-
bition of voltage-gated calcium ion (Ca2+) and potassium
ion (K+) channels have been reported to cause reduc-
tion of breast tumour size.37,38 However, these drugs were
toxic to non-malignant tissues. Cardiac glycosides which
inhibit the Na+/K+-ATPase pump while exerting antitu-
mor effects,39–41 demonstrate higher toxicity to normal
breast epithelial cells than to breast cancer cells.42 In con-
trast, targeting HCN channels appeared to have minimal
effect on normal breast epithelia (Figure 2G, H; 5A-C; 5F;
6F; Supporting information Figure S15A-D).
Apart fromHCN channels, the transient receptor poten-
tial (TRP) channels superfamily, such as TRPC143 and
TRPC5,44 have been shown to be involved in the patho-
genesis of breast cancer. Overexpression of various TRP
channels has been suggested to associate with poorer out-
come of breast cancer.45 TRP channels are responsible for
mediating the import of calcium ions. Therefore, target-
ing TRP channels could be an alternative for targeting
calcium signalling to compromise the survival advantage
of breast cancer cells. Similarly, cyclic nucleotide-gated
(CNG) channels mediate the influx of calcium and sodium
ions through messengers cAMP or cGMP.46 Activation of
CNG channels can trigger various downstream effectors,
such as PKA and PKC, in addition to increasing the level of
calcium which could activate CaMKII.47 Hyperactivation
of PKA can promote tumorigenesis in mammary tissue.48
Activation of CaMKII plays essential roles in the prolifera-
tion, differentiation and survival of various cancer cells.49
Therefore, targeting CNG channels should be able to sup-
press the growth of breast tumours.
We established the minimal subcutaneous dosage of 5
mg/kg Ivabradine twiceweekly (human-equivalent dosage
[HED] 48.78 mg/week (Supporting information Table
S8),50 sufficient to inhibit tumour growth (Figure 3H),
which is below the maximum daily dosage of 15 mg
allowed for humans. More importantly, we found a pro-
found synergistic effect of Ivabradine with paclitaxel, the
combination of both drugs at lowdoses resulting in tumour
regression in vivo (Figure 7O-Q). Paclitaxel inhibits can-
cer cell proliferation by disturbing the formation of micro-
tubules. Such an effect can act on both normal and can-
cerous cells, with side-effects being a common problem.
While low-dose paclitaxel might not effectively eliminate
cancer cells, the addition of Ivabradine, can enable both
drugs to act synergistically. We believe this synergistic
effect is due to ER-stress which serves as a common hub
P < .001. The scale bar represents 5 µm. B, HCN inhibition by Ivabradine significantly induced ER-stress response as measured by ATF4
luciferase reporter activities. Renilla luciferase was used as the internal control. A total of 10 µM of Ivabradine was used to treat the cells for 72
h. Results were shown as mean ± SD from three independent experiments. Students’ t-test was employed to determine statistical significance
between H2O and Ivabradine-treated groups. *** represents P < .001. C, Ivabradine could enhance the protein expression of GRP78 and CHOP
in MDA-MB-231 and MDA-MB-453 but not in MCF-10A. Also, 10 µM of Ivabradine was used to treat the cells for 72 h. Western blot was used
to determine protein expression. Actin was the loading control. Representative image from three independent experiments. D, Ivabradine
enriched the nuclear localization of CHOP. Ten micromolar of Ivabradine was used to treat the cells for 48 h. Nucleocytoplasmic fractionation
was performed to isolate the nuclear fraction. Western blot was used to determine protein expression. Tubulin was a cytoplasmic marker, and
Lamin B1 was a nuclear marker. Representative images from three independent experiments. E, 4-PBA could relieve ER-stress induced by
Ivabradine. A total of 10 µM of Ivabradine and 10 µM of 4-PBA was used to treat the cells for 72 h. Luciferase reporter assay was used to
determine the activity of ATF4. Results were shown as mean ± SD from three independent experiments. One-way ANOVA was used.
Bonferroni was used as post-test of one-way ANOVA to determine the statistical significance between two groups. *** represents P < .001. F,
4-PBA could compromise the growth inhibition effect of Ivabradine on breast cancer cell lines by cell viability assay. MTT assay was
performed after 72 h of treatment. Ten micromolar of Ivabradine and 10 µM of 4-PBA was used. Results were shown as mean ± SD from three
independent experiments. Students’ t-test was employed. *, ** and *** represent P < .05, P < .01 and P < .001, respectively. G, 4-PBA could
compromise the effect of Ivabradine on caspase activation in breast cancer cell lines. Caspase 3/7 Glo assay was performed after 72 h of
treatment. A total of 10 µM of Ivabradine and 10 µM of 4-PBA was used. Results were shown as mean ± SD from three independent
experiments. One-way ANOVA was used. Bonferroni was used as post-test of one-way ANOVA to determine the statistical significance
between two groups. *** represents P < .001. H, 4-PBA could compromise the effect of Ivabradine on apoptosis in breast cancer cell lines.
Annexin V/PI staining was performed. Flow cytometry was employed for cell analysis. Ten micromolar of Ivabradine and 10 µM of 4-PBA was
used. Results were shown as mean ± SD from three independent experiments. One-way ANOVA was used. Bonferroni was used as post-test of
one-way ANOVA to determine the statistical significance between two groups. *** represents P < .001
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F IGURE 6 Knockdown of HNC2- and HCN3-induced ER-stress and apoptosis in breast cancer cells. Knockdown of HCN2 and HCN3 in
A, MDA-MB-231 and B, MDA-MB-453 could enhance the activity of ATF4. The cells were treated with 50 pmol of siHCN2, siHCN3, or
non-targeting siRNA (siCtrl) for 72 h. ER-stress response was determined by ATF4 luciferase reporter assay. Results were shown as mean ±
SD from three independent experiments. Students’ t-test was employed to determine statistical significance between two groups. * and ***
represents P < .05 and P < .001, respectively. C, Knockdown of HCN2 and HCN3 promoted cytochrome c release to cytoplasm. The cells were
treated with 50 pmol of siHCN2, siHCN3 and non-targeting siRNA (siCtrl) for 72 h. Mitochondria Isolation Kit was performed to isolate
cytoplasmic fraction which was free of mitochondria. Western blot was employed to determine the expression of cytochrome c in the fraction.
Tubulin served as loading control and cytoplasmic marker. GAPDH served as mitochondrial marker. Representative image shown from three
independent experiments. Knockdown of HCN2 and HCN3 enhanced caspase activity in D, MDA-MB-231 and E, MDA-MB-453 but not in F,
MCF-10A. The cells were treated with 50 pmol of siHCN2, siHCN3 and non-targeting siRNA (siCtrl) for 72 h. Cell Event Caspase 3/7 Green
Detection Reagent was employed to determine the caspase activity. Infinite F200 microplate reader was employed to record the fluorescent
signal. Results were shown as mean ± SD from three independent experiments. One-way ANOVA was used. Bonferroni was used as post-test
of one-way ANOVA to determine the statistical significance between untreated and siHCN2 or siHCN3 groups. *** represents P < .001.
Knockdown of G, HCN2 and H, HCN3 enhanced ER stress and apoptosis in breast tumor. The tumours were isolated from xenografts
established from MDA-MB-231. Western blot was employed to determine the expression of indicated candidate proteins from three
independent tumours. Tubulin was used as the loading control. Representative image shown from three independent experiments.
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F IGURE 7 The synergistic effect of Ivabradine with paclitaxel. The curve showed the effect of paclitaxel on ER-stress in A, MDA-MB-231
and B, MDA-MB-453. The curve showed the effect of Ivabradine on ER stress in C, MDA-MB-231 and D, MDA-MB-453. The effect of the
addition of 100, 250 and 500 nM of Ivabradine on ER-stress in E, MDA-MB-231 and F, MDA-MB-453 treated with paclitaxel. ER-stress was
determined using luciferase reporter with ATF4 response element. The assay was performed 24 h post drug treatment. Results were shown as
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for Ivabradine and paclitaxel to amplify signals to activate
caspase, thus, initiating cell death at much lower dosages
when using both drugs together.
When combined with Ivabradine, the effective dose of
paclitaxel is 2 mg/kg in mice (HED 19.5 mg/week),50 27-
fold less than the recommended dose (Supporting infor-
mation Table S8) used clinically to treat TNBC. Likewise,
the effective dose of Ivabradine is reduced to 1 mg/kg in
mice, given twice weekly (HED 9.76 mg/week) (Support-
ing information Table S8), which more than 10-fold less
the maximum allowed human dosage of 105 mg per week.
Thus, combination treatment regimen besides being effec-
tive, could minimize systemic toxicity to patients. Promis-
ing future work remains to determine whether this combi-
nation therapymay also be effective for other cancer types.
Recent evidence has suggested HCN channels as phar-
macological targets for analgesia.51 Indeed HCN chan-
nel inhibitors, Ivabradine and Gabapentin, both demon-
strate the anti-nociceptive effect. Given the known side-
effect of paclitaxel of chemotherapy-induced peripheral
neuropathy,52 Ivabradine given in combination with pacli-
taxel might help counteract the neuropathic pain induced
by paclitaxel.
In summary, our findings provide new insight into the
treatment of cancer, particularly TNBC. Given that Ivabra-
dine is the only FDA-approved inhibitor of HCN chan-
nels, its repurposing provides a fast-track drug develop-
ment route.
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mean ± SD from six independent experiments. G, A table showed the EC50 of paclitaxel with or without Ivabradine. Combination Index (CI)
was calculated. The dose-dependent effect of paclitaxel on caspase activities in H, MDA-MB-231 and I, MDA-MB-453. The dose-dependent
effect of Ivabradine on caspase activities in J, MDA-MB-231 and K, MDA-MB-453. Results were shown as mean ± SD from six independent
experiments. One-way ANOVA was used. Bonferroni was used as post-test of one-way ANOVA to determine the statistical significance
between the control (0 nM) and the treatment groups. *** represents P < .001. L, Cotreatment of Ivabradine and paclitaxel could enhance
ER-stress and activate caspases in MDA-MB-231 and MDA-MB-453. Western blot was employed to determine the expression of the indicated
candidate proteins. The addition of 5 µM of 4-PBA could abolish the effect of Ivabradine and paclitaxel cotreatment on caspases activation in
M, MDA-MB-231 and N, MDA-MB-453. The assay was performed after 48 h of the drug treatment. Results were shown as mean ± SD from
three independent experiments. One-way ANOVA was used. Bonferroni was used as post-test of one-way ANOVA to determine the statistical
significance between untreated and the treatment groups. *** represents P < .001. O, The tumor-suppressive effect of Ivabradine and
paclitaxel cotreatment. MDA-MB-231 was employed to establish the xenograft on nude mice. Ivabradine and paclitaxel were administered
subcutaneously twice a week for 4 weeks. The images showed the tumours on the mice and isolated tumours. P, Ivabradine and paclitaxel
cotreatment reduced tumor weight. Each dot represents one tumor in the group. Results were shown as mean ± SD. Two-way ANOVA
revealed there was a statistically significant interaction between the effects of treatment methods and length (F = 7.45, P < .001). Bonferroni
test was used as post-test of two-way ANOVA to determine the statistical significance between saline and treatment group at each of the time
point. *, ** and *** represent P < .05, P < .01 and P < .001 respectively. Q, The effect of Ivabradine and paclitaxel co-treatment on tumor
growth. Results were shown as mean ± SD. One-way ANOVA was used. Bonferroni test was used as post-test of one-way ANOVA to determine
the statistical significance between saline and treatment group at each of the time point. * and **represent P < .05 and P < .01, respectively
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